Vitiligo

This Q&A interview highlights several takeaways from the data on upadacitinib in patients with non-segmental vitiligo (NSV).

Check out exclusive expert interviews of late breaking data from AAD 2026.

New data suggest those who exhibit minimal early response to ruxolitinib cream may still achieve repigmentation with prolonged use extending to 2 years.

AbbVie’s upadacitinib (Rinvoq) has had its regulatory applications submitted to the FDA and the EMA, with the drug being indicated for adults and adolescents with vitiligo.

Ritlecitinib was evaluated for the treatment of non-segmental vitiligo (NSV) in different subgroups, stratified by demographics as well as various clinical characteristics.

Investigators synthesized existing data on psychiatric comorbidities and outcomes related to quality of life in pediatric vitiligo.

This analysis assesses the positive predictive value of the ICD-10 code for vitiligo commonly used in electronic medical record-based research.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

These findings highlight the efficacy and tolerance of treatment with oral baricitinib along with phototherapy among those with the most severe form of vitiligo.

These data highlight long-term complications related to COVID-19 in terms of skin conditions, a continuing concern for many patients.

T-VASI and F-VASI are validated, responsive tools for assessing vitiligo severity and re-pigmentation, with meaningful change thresholds established.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.

Following this pooled analysis, there may be a need for additional research conducted to identify other targets for achievement of optimal repigmentation.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

Thierry Passeron, MD, PhD, discusses the potential benefit of upadacitinib as an oral systemic therapy in patients with nonsegmental vitiligo.

Hamzavi discusses new late-breaking data from AAD 2024, including major takeaways and safety profile after 52 weeks.

These data highlight the severe economic burden faced by patients with vitiligo compared to that of the general population, including mental health-related costs.

Vitiligo was significantly associated with an increased risk of bacteremia, cellulitis, and herpes zoster and was more common among those with female sex, Black compared to White race, Hispanic ethnicity, hepatitis C infection, and tobacco use.

These data indicate the necessity of further research to clarify any associations between COVID-19 infection, the virus’s associated vaccines, and progression of vitiligo.

These findings may require further evaluation using classification of age range as well as severity of disease, allowing for more precise results.

These data indicate that the early detection of vitiligo may be improved through an assessment of transplant recipients and using a multidisciplinary approach.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

This new data indicates the necessity of health providers around the world to address the mental health needs of vitiligo patients, especially among those most heavily affected.

This interview with Dr. Chovatiya featured a discussion about new findings from a recent study on epidemiologic data on vitiligo in the US.

While the unmet needs of patients of color is a growing concern in the dermatology world, more has to be done to address the obvious disparities in care.